The EPS miss and lack of revenue growth reinforce the pre-revenue clinical-stage profile. The setrusumab regulatory path remains uncertain after Phase 3 failures, and alvelestat partnership timing is unknown. Monitor for regulatory feedback on setrusumab and any partnership announcement for alvelestat, which could be a catalyst. Cash runway into mid-2027 provides some buffer but limits upside without a deal.
Price Chart
Executive Summary
Mereo BioPharma reported Q1 2026 EPS of -$0.01, missing the $0.00 consensus estimate, with revenue not explicitly stated but net loss improving to $6.7M from $12.9M a year ago. The company highlighted ongoing regulatory discussions for setrusumab in osteogenesis imperfecta and partnership talks for alvelestat, but the Phase 3 studies for setrusumab failed to meet primary endpoints, tempering near-term catalysts.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.01 missed consensus estimate of $0.00 (a 4100% miss vs near-zero base).
- Net loss improved to $6.7M from $12.9M in Q1 2025, driven by lower G&A expenses.
- Cash and cash equivalents stood at $36.2M as of March 31, 2026, down from $41.0M at year-end 2025.
- Setrusumab Phase 3 studies (Orbit and Cosmic) failed to meet primary endpoints on fracture reduction, though key secondary endpoints on bone mineral density and patient-reported outcomes were met.
- Company initiated regulatory agency interactions for setrusumab in pediatric OI, but no clear path to approval yet.
- Alvelestat partnership discussions ongoing; Phase 3 could start within 6 months of a deal.
- Vantictumab Phase 2 trial in osteopetrosis expected to start H2 2026, funded by partner āshibio.
- Cash runway expected into mid-2027, excluding potential business development payments.
Financial Impact
EPS miss of $0.01 vs $0.00 consensus; net loss of $6.7M vs $12.9M YoY improvement; cash burn of ~$4.8M in Q1
Risk Factors
- Setrusumab may fail to gain regulatory approval after Phase 3 miss on primary endpoints.
- Alvelestat partnership may not materialize or be on unfavorable terms.
- Cash burn rate may accelerate if clinical programs expand without partner funding.
- Dilution risk from potential equity offerings to fund operations beyond mid-2027.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292715 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 9w ago | 8-K | $0.3115 $0.2780 | ▲ +10.75% | ▲ +10.37% | $0.2917 (+6.36%) |
Aug 11, 2026 11w ago | 8-K | $0.3060 $0.3130 | ▲ +2.29% | ▲ +2.69% | $0.2917 (−4.67%) |
Aug 11, 2026 11w ago | Press Release | $0.3060 $0.3130 | ▲ +2.29% | ▲ +2.69% | $0.2917 (−4.67%) |
Aug 11, 2026 11w ago | 8-K | $0.3060 $0.3130 | ▲ +2.29% | ▲ +2.69% | $0.2917 (−4.67%) |
Jun 11, 2026 19w ago | Institutional Cluster | $0.3118 $0.3100 | ▼ −0.58% | ▼ −1.01% | $0.2917 (−6.45%) |
May 12, 2026 24w ago | Press Release | $0.2460 $0.2370 | ▲ +3.66% | ▲ +3.74% | $0.2917 (−18.58%) |
Mar 19, 2026 31w ago | Press Release | $0.3610 $0.3390 | ▼ −6.09% | ▼ −3.88% | $0.2917 (−19.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers